风湿性多肌痛中亚临床血管炎的患病率、特征与结局:一项回顾性队列研究
该回顾性队列纳入2003至2020年间接受FDG PET检查且随访≥6个月的337例孤立性风湿性多肌痛症状患者,其中31例(9%)存在亚临床血管炎,以大血管炎为主;亚临床血管炎组诊断后12个月内糖皮质激素起始剂量及随访期间剂量更高,但停药比例与复发比例无显著差异。
要点
- 337例风湿性多肌痛患者中31例(9%)存在亚临床血管炎。
- 亚临床血管炎以大血管炎为主,孤立性大血管炎21例(58%)。
- 亚临床血管炎组诊断后12个月内糖皮质激素剂量更高,但停药比例与复发比例无显著差异。
核心结论
- 本中心风湿性多肌痛患者中仅9%存在亚临床血管炎,且以大血管炎为主。
- 亚临床血管炎组与无亚临床血管炎组的复发比例和糖皮质激素治疗时长无差异,但前者诊断后12个月内接受更高糖皮质激素剂量。
- 作者认为需要前瞻性干预试验来评估采用相似糖皮质激素方案治疗的伴或不伴亚临床血管炎的风湿性多肌痛患者的结局。
研究设计与样本
- 回顾性纳入2003至2020年间接受FDG PET检查、随访≥6个月的连续孤立性风湿性多肌痛症状的GCA/PMR谱系病患者。
- 共纳入337例患者,血管炎定义为任何血管FDG摄取≥2级。
主要发现
- 337例中31例(9%)存在亚临床血管炎。
- 亚临床血管炎患者中,孤立性大血管炎21例(58%),孤立性颅血管炎3例(10%),颅血管炎合并大血管炎7例(23%)。
- 亚临床血管炎组诊断后12个月内糖皮质激素起始剂量及随访期间剂量更高(P < 0.001)。
- 糖皮质激素治疗时长两组分别为25个月与20个月(P = 0.187)。
- Cox比例风险回归分析显示,停药比例(HR 0.78 [95% CI 0.49-1.25],P = 0.303)与复发比例(HR 0.82 [95% CI 0.50-1.36],P = 0.441)均无差异。
关键数值与推荐
- 亚临床血管炎定义为任何血管FDG摄取≥2级。
- 糖皮质激素治疗时长:亚临床血管炎组25个月 vs 无亚临床血管炎组20个月(P = 0.187)。
- 停药比例:HR 0.78(95% CI 0.49-1.25),P = 0.303。
- 复发比例:HR 0.82(95% CI 0.50-1.36),P = 0.441。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需要前瞻性干预试验来评估采用相似糖皮质激素方案治疗的伴或不伴亚临床血管炎的风湿性多肌痛患者的结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Two recent meta-analyses reported subclinical vasculitis in 22-23% of patients with PMR. We aimed to evaluate the prevalence, characteristics, and outcome of subclinical vasculitis among our PMR patients. METHODS: Consecutive patients with GCA/PMR spectrum disease with isolated PMR symptoms who underwent FDG PET imaging between 2003 and 2020 and who were followed for ≥6 months, were included retrospectively. Vasculitis was defined as FDG uptake ≥grade 2 in any vessel. RESULTS: We included 337 patients, of whom 31 (9%) with subclinical vasculitis. Among those with subclinical vasculitis, 21 (58%) had isolated large vessel vasculitis, 3 (10%) had isolated cranial vasculitis and 7 (23%) had both cranial and large vessel vasculitis. The glucocorticoid (GC) starting dose and GC doses during follow-up were higher in those with subclinical vasculitis until 12 months after diagnosis (P < 0.001). There was no difference in the duration of GC treatment (25 vs 20 months, P = 0.187). Cox proportional hazard regression analyses showed no difference in the proportion of patients able to stop GC (HR 0.78 [95% CI 0.49-1.25], P = 0.303) and in the proportion of patients with relapse (HR 0.82 [95%CI 0.50-1.36], P = 0.441). CONCLUSION: Only 9% of our PMR patients had subclinical vasculitis with a predilection for large vessel vasculitis. There were no differences in relapse rate and duration of GC treatment, however, those with subclinical vasculitis received higher GC doses until 12 months after diagnosis. Prospective interventional trials are needed to evaluate the outcome of PMR patients with and without subclinical vasculitis treated with a similar GC protocol.
引用
- Moreel L, Boeckxstaens L, Betrains A, et al. Prevalence, characteristics, and outcome of subclinical vasculitis in polymyalgia rheumatica: a retrospective cohort study. Rheumatology (Oxford). 2024. PMID: 38547403. doi:10.1093/rheumatology/keae208
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。